Blog

The FDA has approved Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for certain adults with unresectable advanced cutaneous melanoma whose cancer progressed after PD-1 therapy. This new advanced melanoma treatment offers another option for patients facing treatment-resistant disease. What Is Tudriqev? Tudriqev is an oncolytic viral therapy designed to target cancer cells and stimulate an immune response. Treatment involves injections directly into tum